ArticleSubstance abuse2016
Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.
Article in Substance abuse, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Adjunct interventions to standard medical management of buprenorphine in outpatient settings: A systematic review of the evidence.Drug and alcohol dependence · 2021Pooled it
- Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial.The lancet. HIV · 2019Trial
- "You don't have the right resources to let it hurt": How structural vulnerabilities shape opioid withdrawal experiences among a community sample of people who inject drugs in Los Angeles, California.Harm reduction journal · 2025Article
- How do restrictions on opioid prescribing, harm reduction, and treatment coverage policies relate to opioid overdose deaths in the United States in 2013-2020? An application of a new state opioid policy scale.The International journal on drug policy · 2025Article
- Utilization of Medications for Opioid Use Disorder Among West Virginia Medicaid Enrollees Following Medicaid Coverage of Methadone.Substance use & addiction journal · 2024Article
- Opioid use disorder treatment and the role of New Jersey Medicaid policy changes: perspectives of office-based buprenorphine providers.The American journal of drug and alcohol abuse · 2023Article
- Exploring the Association of State Policies and the Trajectories of Buprenorphine Prescriber Patient Caseloads.Substance abuse · 2023Article
- Cost-effectiveness of Increasing Buprenorphine Treatment Initiation, Duration, and Capacity Among Individuals Who Use Opioids.JAMA health forum · 2023Article
- Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment.JAMA health forum · 2023Article
- Variation in adverse drug events of opioids in the United States.Frontiers in pharmacology · 2023Article
- Sociodemographic differences in quality of treatment to Medicaid enrollees receiving buprenorphine.Substance abuse · 2022Article
- Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy.The New England journal of medicine · 2022Article
- Buprenorphine treatment episode duration, dosage, and concurrent prescribing of benzodiazepines and opioid analgesics: The effects of Medicaid prior authorization policies.Drug and alcohol dependence · 2022Article
- The effects of opioid policy changes on transitions from prescription opioids to heroin, fentanyl and injection drug use: a qualitative analysis.Substance abuse treatment, prevention, and policy · 2022Article
- Methocinnamox Reverses and Prevents Fentanyl-Induced Ventilatory Depression in Rats.The Journal of pharmacology and experimental therapeutics · 2021Article
- Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: a Rapid Review.Journal of general internal medicine · 2020Review
- The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.Health services research · 2020Article
- Strengths and weaknesses of existing data sources to support research to address the opioids crisis.Preventive medicine reports · 2020Review
- Organizational factors associated with practitioners' support for treatment of opioid use disorder in the emergency department.Addictive behaviors · 2020Article
- Improving Access to Evidence-Based Medical Treatment for Opioid Use Disorder: Strategies to Address Key Barriers within the Treatment System.NAM perspectives · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundState Medicaid policies play an important role in Medicaid enrollees' access to and use of opioid agonists, such as methadone and buprenorphine, in the treatment of opioid use disorders. Little information is available, however, regarding the evolution of state policies facilitating or hindering access to opioid agonists among Medicaid enrollees.
methodsDuring 2013-2014, we surveyed state Medicaid officials and other designated state substance abuse treatment specialists about their state's recent history of Medicaid coverage and policies pertaining to methadone and buprenorphine. We describe the evolution of such coverage and policies and present an overview of the Medicaid policy environment with respect to opioid agonist therapy from 2004 to 2013.
resultsAmong our sample of 45 states with information on buprenorphine and methadone coverage, we found a gradual trend toward adoption of coverage for opioid agonist therapies in state Medicaid agencies. In 2013, only 11% of states in our sample (n = 5) had Medicaid policies that excluded coverage for methadone and buprenorphine, whereas 71% (n = 32) had adopted or maintained policies to cover both buprenorphine and methadone among Medicaid enrollees. We also noted an increase in policies over the time period that may have hindered access to buprenorphine and/or methadone.
conclusionsThere appears to be a trend for states to enact policies increasing Medicaid coverage of opioid agonist therapies, while in recent years also enacting policies, such as prior authorization requirements, that potentially serve as barriers to opioid agonist therapy utilization. Greater empirical information about the potential benefits and potential unintended consequences of such policies can provide policymakers and others with a more informed understanding of their policy decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.